title: [Peripartum cardiomyopathy].
abstract: Peripartum cardiomyopathy is a rare and potentially fatal disease with peripartum heart failure in previously healthy women. A brief review of the literature is provided with emphasis on recent data indicating that an antiangiogenic cleavage product of prolactin contributes to the molecular mechanisms underlying peripartum cardiomyopathy, and that blocking the release of prolactin with bromocriptine can ameliorate the condition.
authors.affiliation: Gentofte Hospital, Kardiologisk Afdeling P, DK-2900 Hellerup. dimabr01@geh.regionh.dk
authors.forename: Ditte-Marie
authors.initials: DM
authors.lastname: Bretler
authors.forename: Casper Haslund
authors.initials: CH
authors.lastname: Jørgensen
authors.forename: Jonas Bjerring
authors.initials: JB
authors.lastname: Olesen
authors.forename: Gunnar Hilmar
authors.initials: GH
authors.lastname: Gislason
authors.forename: Peter Riis
authors.initials: PR
authors.lastname: Hansen
mesh_terms: D001971:Bromocriptine / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011644:Puerperal Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D012307:Risk Factors
chemical_list: D006727:Hormone Antagonists; D001971:Bromocriptine